Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137124
Status:
COMPLETED
Last Update Posted:
2012-07-10
First Post:
2005-08-26
Brief Title:
L-Arginine Metabolism in Essential Hypertension
Sponsor:
University of Erlangen-Nürnberg Medical School
Organization:
University of Erlangen-Nürnberg Medical School
Study Overview
Official Title:
Transport and Metabolism of L-arginine Role for Endothelial Dysfunction in Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Essential hypertension is characterized by impaired endothelial function Data derived from normotensive subjects with a genetic predisposition to arterial hypertension suggest that endothelial dysfunction is a cause rather than a consequence of the condition Given that in normotensive offspring of hypertensive parents impaired endothelium dependent vasodilation can be restored by supplementation of the nitric oxide NO precursor L-arginine a defect in the L-arginineNO pathway can be postulated The investigators at the University of Erlangen-Nuremberg hypothesize that impaired endothelial function in essential hypertension is associated with alterations in L-arginine metabolism and transport This study will determine whether metabolism and transport of L-arginine are altered in patients with essential hypertension and whether these potential alterations can be targeted therapeutically
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None